Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies

被引：0
|
作者：
G. S. Falchook
M. Duvic
D. S. Hong
J. Wheler
A. Naing
J. Lim
R. Kurzrock
机构：
[1] The University of Texas MD Anderson Cancer Center,Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program)
[2] The University of Texas MD Anderson Cancer Center,Unit 455
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Bortezomib; Gemcitabine; Liposomal doxorubicin; Cutaneous T-cell lymphoma; Small cell carcinoma; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1117 / 1126
页数：9
相关论文
共 50 条
  • [21] PHASE I TRIAL OF BORTEZOMIB AND CONCURRENT EXTERNAL BEAM RADIATION IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
    Pugh, Thomas J.
    Chen, Changhu
    Rabnovitch, Rachel
    Eckhardt, S. Gail
    Rusthoven, Kyle E.
    Swing, Robyn
    Raben, David
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (02): : 521 - 526
  • [22] Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
    G Del Conte
    C Sessa
    R von Moos
    L Viganò
    T Digena
    A Locatelli
    E Gallerani
    A Fasolo
    A Tessari
    R Cathomas
    L Gianni
    British Journal of Cancer, 2014, 111 : 651 - 659
  • [23] Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies
    Fracasso, PM
    Rodriguez, LC
    Herzog, TJ
    Fears, CL
    Goodner, SA
    Govindan, R
    Picus, J
    Rader, JS
    Tan, BR
    Arquette, MA
    CANCER, 2003, 98 (03) : 610 - 617
  • [24] Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
    Del Conte, G.
    Sessa, C.
    von Moos, R.
    Vigano, L.
    Digena, T.
    Locatelli, A.
    Gallerani, E.
    Fasolo, A.
    Tessari, A.
    Cathomas, R.
    Gianni, L.
    BRITISH JOURNAL OF CANCER, 2014, 111 (04) : 651 - 659
  • [25] Phase 1 Trial of Gemcitabine With Bortezomib in Elderly Patients With Advanced Solid Tumors
    Bommakanti, Satya V.
    Dudek, Arkadiusz Z.
    Khatri, Amit
    Kirstein, Mark N.
    Gada, Purvi D.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (06): : 597 - 602
  • [26] Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial
    John Hayslip
    Uzair Chaudhary
    Mark Green
    Mario Meyer
    Steven Dunder
    Carol Sherman
    Shanta Salzer
    Andrew Kraft
    Alberto J Montero
    BMC Cancer, 7
  • [27] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Kusumoto, Shigeru
    Sunami, Kazutaka
    Inagaki, Mitsuo
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 578 - 584
  • [28] Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy
    Keith T. Flaherty
    James P. Stevenson
    Stephen M. Hahn
    Maryann Redlinger
    Peter J. O'Dwyer
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 217 - 222
  • [29] Phase 1 study of pegylated liposomal doxorubin and gemcitabine in patients with advanced malignancies
    Fracasso, PM
    Blum, KA
    Tan, BR
    Fears, CL
    Bartlett, NL
    Arquette, MA
    Clark, RS
    CANCER, 2002, 95 (10) : 2223 - 2229
  • [30] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Shigeru Kusumoto
    Kazutaka Sunami
    Mitsuo Inagaki
    Shinsuke Iida
    International Journal of Hematology, 2015, 101 : 578 - 584
12345